Developer docs
API playgroundTry for free, no card

Search company profiles

Lytix Biopharma

Full company profile

uuid0000qd2

Namestring
Lytix Biopharma
Legal namestring
Lytix Biopharma ASA
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Lytix Biopharma ASA is a clinical-stage Norwegian biopharmaceutical company developing oncolytic molecule immunotherapies derived from host-defense peptides for the treatment of solid tumors. The company's lead candidate, ruxotemitide (LTX-315; also known as VP-315 under license), is administered intratumorally and works through a two-step mechanism: it lyses cancer cell membranes to release tumor antigens and immunostimulatory danger signals, then activates a broad T-cell response that produces durable systemic (abscopal) anti-tumor immunity. Ruxotemitide is in Phase II development for neoadjuvant resectable melanoma in combination with pembrolizumab (NeoLIPA study), and has reported 51% complete response and 97% clinical response rates in basal cell carcinoma under a 2017 exclusive worldwide license to Verrica Pharmaceuticals covering dermatologic indications. A second pipeline asset, LTX-401, targets deep-seated solid tumors including liver cancer via image-guided intratumoral delivery and is in late-stage pre-clinical development.

The company's underlying technology is a proprietary oncolytic peptide platform protected by an extensive patent estate across major pharmaceutical markets and supported by publications in journals such as the Journal for ImmunoTherapy of Cancer, Clinical Cancer Research, Frontiers in Immunology, and OncoImmunology. Its Scientific Advisory Board includes Nobel Laureate James Allison. The business model is partnership-driven: Lytix is pre-revenue from product sales and generates income via licensing royalties and milestone payments from partners. Its sole commercial-stage counterparty is Verrica Pharmaceuticals for dermatology, and it is actively seeking additional co-development and outlicensing partners for ruxotemitide in Asia/APAC and for LTX-401 in deep-seated tumors. The company is listed on Euronext Growth Oslo under ticker LYTIX (ISIN: NO0010405780) since June 2021, converted from AS to ASA in April 2026, and as of February 2026 had 76,900,005 shares outstanding with NOK 72.4 million in cash and short-term investments at year-end 2025.

Short descriptiontext

Lytix Biopharma ASA is a clinical-stage Norwegian biotech developing intratumoral oncolytic peptide immunotherapies (ruxotemitide, LTX-401) that lyse cancer cells and activate systemic immunity, serving cancer patients with solid tumors through licensing partnerships such as Verrica Pharmaceuticals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOslo, Norway
HQ citystring
Oslo
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncolytic immunotherapy, immuno-oncology drugs, host-defense peptides, cancer therapeutics, neoadjuvant oncology
Industry2 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAKAFAB
Medical Oncology
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Immuno-oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing Royalties
TypeLicensing Royalties
Description

Lytix generates revenue through licensing agreements with partners. Verrica Pharmaceuticals holds an exclusive worldwide license for dermatological oncology indications (basal cell carcinoma and squamous cell carcinoma). Lytix receives milestone payments and royalties from these licensing arrangements.

lytixbiopharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lytix Biopharma is a clinical-stage biopharmaceutical company developing a pipeline of oncolytic molecule immunotherapies derived from host-defense peptides. Its lead asset ruxotemitide (LTX-315/VP-315) is being advanced toward registrational studies for neoadjuvant melanoma in combination with pembrolizumab, with additional development in basal cell carcinoma via a licensing partnership with Verrica Pharmaceuticals. A second pipeline candidate, LTX-401, targets deep-seated solid tumors such as liver cancer using image-guided intratumoral delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 51% complete response rate in basal cell carcinoma Phase II study
+4 more records
Product overview1 text field

Lytix Biopharma is a clinical-stage biotech company developing a platform of oncolytic molecule immunotherapies derived from host-defense peptides. The core product is ruxotemitide (LTX-315/VP-315), an oncolytic peptide approaching registrational studies for neoadjuvant melanoma in combination with pembrolizumab, with monotherapy indication in basal cell carcinoma via partnership with Verrica Pharmaceuticals. A second pipeline asset, LTX-401, is in pre-clinical development for deep-seated solid tumors including liver cancer. The company operates through direct clinical programs and licensing partnerships, focusing on intratumoral administration that destroys cancer cells and activates systemic immune responses.

Product and service2 records
1Ruxotemitide (LTX-315 / VP-315)
CategoryOncolytic Peptide Immunotherapy
Description

First-in-class oncolytic peptide that destroys cancer cell membranes via intratumoral injection, releasing tumor antigens and immunostimulatory molecules that initiate a broad immune cell response. It is being developed for neoadjuvant resectable melanoma in combination with pembrolizumab, with monotherapy development in basal cell carcinoma via the Verrica partnership. Phase II data show a 51% complete response rate and 97% clinical response rate in basal cell carcinoma and approximately 90% pathological responses in combination with pembrolizumab in melanoma.

2LTX-401
CategoryOncolytic Peptide Immunotherapy
Description

Second-generation oncolytic molecule from Lytix's host-defense peptide platform, designed for deep-seated solid tumors such as liver cancer. It is administered via image-guided intratumoral delivery and has demonstrated proof-of-concept in animal models, including curing animals of liver cancer. The asset is in late-stage pre-clinical development and the company is actively seeking a development partner.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCore/FlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2017-01-01
Description

Verrica Pharmaceuticals holds an exclusive worldwide license agreement with Lytix Biopharma to develop and commercialize ruxotemitide (LTX-315, VP-315) for dermatologic oncology conditions, including basal cell carcinoma and squamous cell carcinoma. Verrica has completed a Phase II study demonstrating 51% complete response rate and 97% clinical response rate in basal cell carcinoma patients. The partnership covers dermatology indications only.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Verrica is Lytix's exclusive worldwide licensee for dermatological oncology indications (BCC, SCC) of ruxotemitide (VP-315). It is a Nasdaq-listed dermatology-focused commercial-stage partner developing the same asset, making it the most directly comparable counterparty in Lytix's portfolio.

TypeDirect peer
Description

Norwegian clinical-stage biotech developing antigen-presenting therapeutic vaccines and immunotherapies for oncology and infectious diseases. Comparable as a Norway-headquartered, publicly-listed immuno-oncology platform biotech at a similar development stage.

TypeDirect peer
Description

Clinical-stage US biotech developing a portfolio of oncolytic immunotherapies (RP1, RP2, RP3) using engineered herpes simplex virus. Comparable as a pure-play oncolytic-immunotherapy developer pursuing intratumoral delivery and combination with checkpoint inhibitors.

TypeDirect peer
Description

Finnish clinical-stage biotech developing oncolytic adenoviruses armed with cytokines (e.g., TILT-123) for solid tumor immunotherapy. Comparable as a Nordic-region oncolytic-immunotherapy company combining local tumor lysis with immune activation, similar in scale and stage.

5Turnstone Biologics
TypeDirect peer
Description

Clinical-stage biotech developing oncolytic virus immunotherapies (e.g., TBio-6517) combined with adoptive cell therapies for solid tumors. Comparable as an oncolytic-immunotherapy developer focused on turning 'cold' tumors 'hot.'

TypeDirect peer
Description

Clinical-stage biotech developing oncolytic vaccinia virus platforms (e.g., GL-ONC1, Olvi-Vec) for solid tumors. Comparable as a clinical-stage oncolytic-virus immunotherapy company pursuing intratumoral administration across multiple tumor types.

7Istari Oncology
TypeDirect peer
Description

Clinical-stage biotech developing PVSRIPO, an oncolytic poliovirus immunotherapy, with lead programs in glioblastoma and melanoma. Comparable as a clinical-stage intratumoral oncolytic-immunotherapy developer exploring checkpoint-inhibitor combinations.

TypeEmerging player
Description

Clinical-stage biotech developing conditionally activated INDUKINE molecules (PREDATOR platform) designed to be active within the tumor microenvironment. Comparable as an immuno-oncology company pursuing tumor-localized activation to overcome systemic immunotherapy limitations.

TypeBroad incumbent
Description

Global commercial-stage immuno-oncology company developing mRNA cancer vaccines, bispecifics, and combination immunotherapies (including checkpoint-inhibitor combinations). Comparable as a leader in next-generation immuno-oncology combinations, though broader and far more advanced than Lytix.

TypeDirect peer
Description

Clinical-stage biotech developing oncolytic adenovirus DNX-2401 (tasadenoturev) for glioblastoma and other solid tumors. Comparable as a clinical-stage intratumoral oncolytic-virus immunotherapy developer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lytix Biopharma

Immuno-oncology Therapeuticslytixbiopharma.com

Lytix Biopharma ASA is a clinical-stage Norwegian biotech developing intratumoral oncolytic peptide immunotherapies (ruxotemitide, LTX-401) that lyse cancer cells and activate systemic immunity, serving cancer patients with solid tumors through licensing partnerships such as Verrica Pharmaceuticals.

What Lytix Biopharma does

Lytix Biopharma ASA is a clinical-stage Norwegian biopharmaceutical company developing oncolytic molecule immunotherapies derived from host-defense peptides for the treatment of solid tumors. The company's lead candidate, ruxotemitide (LTX-315; also known as VP-315 under license), is administered intratumorally and works through a two-step mechanism: it lyses cancer cell membranes to release tumor antigens and immunostimulatory danger signals, then activates a broad T-cell response that produces durable systemic (abscopal) anti-tumor immunity. Ruxotemitide is in Phase II development for neoadjuvant resectable melanoma in combination with pembrolizumab (NeoLIPA study), and has reported 51% complete response and 97% clinical response rates in basal cell carcinoma under a 2017 exclusive worldwide license to Verrica Pharmaceuticals covering dermatologic indications. A second pipeline asset, LTX-401, targets deep-seated solid tumors including liver cancer via image-guided intratumoral delivery and is in late-stage pre-clinical development.

The company's underlying technology is a proprietary oncolytic peptide platform protected by an extensive patent estate across major pharmaceutical markets and supported by publications in journals such as the Journal for ImmunoTherapy of Cancer, Clinical Cancer Research, Frontiers in Immunology, and OncoImmunology. Its Scientific Advisory Board includes Nobel Laureate James Allison. The business model is partnership-driven: Lytix is pre-revenue from product sales and generates income via licensing royalties and milestone payments from partners. Its sole commercial-stage counterparty is Verrica Pharmaceuticals for dermatology, and it is actively seeking additional co-development and outlicensing partners for ruxotemitide in Asia/APAC and for LTX-401 in deep-seated tumors. The company is listed on Euronext Growth Oslo under ticker LYTIX (ISIN: NO0010405780) since June 2021, converted from AS to ASA in April 2026, and as of February 2026 had 76,900,005 shares outstanding with NOK 72.4 million in cash and short-term investments at year-end 2025.

Lytix Biopharma firmographics

Firmographics
Name
Lytix Biopharma
Legal name
Lytix Biopharma ASA
Website
https://lytixbiopharma.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Lytix Biopharma ASA is a clinical-stage Norwegian biotech developing intratumoral oncolytic peptide immunotherapies (ruxotemitide, LTX-401) that lyse cancer cells and activate systemic immunity, serving cancer patients with solid tumors through licensing partnerships such as Verrica Pharmaceuticals.
Ownership category
akta.pro rank

Lytix Biopharma industry classification

Industry
Product category
Immuno-oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAKAFAB
Medical Oncology

Keywords

  • Oncolytic immunotherapy
  • Immuno-oncology drugs
  • Host-defense peptides
  • Cancer therapeutics
  • Neoadjuvant oncology

Where Lytix Biopharma is headquartered

Location

Headquarters

HQ city
Oslo
HQ country
Norway
HQ region
Europe

Offices1 record

Markets served

Lytix Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing Royalties: Lytix generates revenue through licensing agreements with partners. Verrica Pharmaceuticals holds an exclusive worldwide license for dermatological oncology indications (basal cell carcinoma and squamous cell carcinoma). Lytix receives milestone payments and royalties from these licensing arrangements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Lytix Biopharma product offering

Product offering

Core offering

Lytix Biopharma is a clinical-stage biopharmaceutical company developing a pipeline of oncolytic molecule immunotherapies derived from host-defense peptides. Its lead asset ruxotemitide (LTX-315/VP-315) is being advanced toward registrational studies for neoadjuvant melanoma in combination with pembrolizumab, with additional development in basal cell carcinoma via a licensing partnership with Verrica Pharmaceuticals. A second pipeline candidate, LTX-401, targets deep-seated solid tumors such as liver cancer using image-guided intratumoral delivery.

Product overview

Lytix Biopharma is a clinical-stage biotech company developing a platform of oncolytic molecule immunotherapies derived from host-defense peptides. The core product is ruxotemitide (LTX-315/VP-315), an oncolytic peptide approaching registrational studies for neoadjuvant melanoma in combination with pembrolizumab, with monotherapy indication in basal cell carcinoma via partnership with Verrica Pharmaceuticals. A second pipeline asset, LTX-401, is in pre-clinical development for deep-seated solid tumors including liver cancer. The company operates through direct clinical programs and licensing partnerships, focusing on intratumoral administration that destroys cancer cells and activates systemic immune responses.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ruxotemitide (LTX-315 / VP-315) First-in-class oncolytic peptide that destroys cancer cell membranes via intratumoral injection, releasing tumor antigens and immunostimulatory molecules that initiate a broad immune cell response. It is being developed for neoadjuvant resectable melanoma in combination with pembrolizumab, with monotherapy development in basal cell carcinoma via the Verrica partnership. Phase II data show a 51% complete response rate and 97% clinical response rate in basal cell carcinoma and approximately 90% pathological responses in combination with pembrolizumab in melanoma.
  • LTX-401 Second-generation oncolytic molecule from Lytix's host-defense peptide platform, designed for deep-seated solid tumors such as liver cancer. It is administered via image-guided intratumoral delivery and has demonstrated proof-of-concept in animal models, including curing animals of liver cancer. The asset is in late-stage pre-clinical development and the company is actively seeking a development partner.

Quantifiable outcome

  • 51% complete response rate in basal cell carcinoma Phase II study
  • +4 more outcomes

Companies that use Lytix Biopharma

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Lytix Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Lytix Biopharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Verrica Pharmaceuticalscore/flagshipOEM/ Whitelabel/ Licensing Partner · 1 January 2017Verrica Pharmaceuticals holds an exclusive worldwide license agreement with Lytix Biopharma to develop and commercialize ruxotemitide (LTX-315, VP-315) for dermatologic oncology conditions, including basal cell carcinoma and squamous cell carcinoma. Verrica has completed a Phase II study demonstrating 51% complete response rate and 97% clinical response rate in basal cell carcinoma patients. The partnership covers dermatology indications only.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Lytix Biopharma competitors and assessment

Company assessment

Direct peers

  • Verrica Pharmaceuticals: Verrica is Lytix's exclusive worldwide licensee for dermatological oncology indications (BCC, SCC) of ruxotemitide (VP-315). It is a Nasdaq-listed dermatology-focused commercial-stage partner developing the same asset, making it the most directly comparable counterparty in Lytix's portfolio.
  • Nykode Therapeutics: Norwegian clinical-stage biotech developing antigen-presenting therapeutic vaccines and immunotherapies for oncology and infectious diseases. Comparable as a Norway-headquartered, publicly-listed immuno-oncology platform biotech at a similar development stage.
  • Replimune: Clinical-stage US biotech developing a portfolio of oncolytic immunotherapies (RP1, RP2, RP3) using engineered herpes simplex virus. Comparable as a pure-play oncolytic-immunotherapy developer pursuing intratumoral delivery and combination with checkpoint inhibitors.
  • TILT Biotherapeutics: Finnish clinical-stage biotech developing oncolytic adenoviruses armed with cytokines (e.g., TILT-123) for solid tumor immunotherapy. Comparable as a Nordic-region oncolytic-immunotherapy company combining local tumor lysis with immune activation, similar in scale and stage.
  • Turnstone Biologics: Clinical-stage biotech developing oncolytic virus immunotherapies (e.g., TBio-6517) combined with adoptive cell therapies for solid tumors. Comparable as an oncolytic-immunotherapy developer focused on turning 'cold' tumors 'hot.'
  • Genelux Corporation: Clinical-stage biotech developing oncolytic vaccinia virus platforms (e.g., GL-ONC1, Olvi-Vec) for solid tumors. Comparable as a clinical-stage oncolytic-virus immunotherapy company pursuing intratumoral administration across multiple tumor types.
  • Istari Oncology: Clinical-stage biotech developing PVSRIPO, an oncolytic poliovirus immunotherapy, with lead programs in glioblastoma and melanoma. Comparable as a clinical-stage intratumoral oncolytic-immunotherapy developer exploring checkpoint-inhibitor combinations.
  • DNAtrix: Clinical-stage biotech developing oncolytic adenovirus DNX-2401 (tasadenoturev) for glioblastoma and other solid tumors. Comparable as a clinical-stage intratumoral oncolytic-virus immunotherapy developer.

Emerging players

  • Werewolf Therapeutics: Clinical-stage biotech developing conditionally activated INDUKINE molecules (PREDATOR platform) designed to be active within the tumor microenvironment. Comparable as an immuno-oncology company pursuing tumor-localized activation to overcome systemic immunotherapy limitations.

Broad incumbents

  • BioNTech: Global commercial-stage immuno-oncology company developing mRNA cancer vaccines, bispecifics, and combination immunotherapies (including checkpoint-inhibitor combinations). Comparable as a leader in next-generation immuno-oncology combinations, though broader and far more advanced than Lytix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Lytix Biopharma social profiles

Digital presence

Lytix Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lytix Biopharma leadership team

Management profile

Number of profiles

Profiles7 records

Lytix Biopharma funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lytix Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lytix Biopharma

What does Lytix Biopharma do?

Lytix Biopharma is a clinical-stage biopharmaceutical company developing a pipeline of oncolytic molecule immunotherapies derived from host-defense peptides. Its lead asset ruxotemitide (LTX-315/VP-315) is being advanced toward registrational studies for neoadjuvant melanoma in combination with pembrolizumab, with additional development in basal cell carcinoma via a licensing partnership with Verrica Pharmaceuticals. A second pipeline candidate, LTX-401, targets deep-seated solid tumors such as liver cancer using image-guided intratumoral delivery.

Is Lytix Biopharma a public or private company?

Lytix Biopharma is a public company. It is classified as public and is currently operating.

When was Lytix Biopharma founded?

Lytix Biopharma was founded in 2013. It employs 11 to 50 people.

Where is Lytix Biopharma based?

Lytix Biopharma is headquartered in Oslo, Norway, in the Europe region.

How does Lytix Biopharma make money?

One revenue line is on record: licensing Royalties.

Who are Lytix Biopharma's main competitors?

Direct peers on record are Verrica Pharmaceuticals, Nykode Therapeutics, Replimune, TILT Biotherapeutics, Turnstone Biologics, Genelux Corporation, Istari Oncology and DNAtrix. Werewolf Therapeutics is listed as an emerging player. BioNTech is listed as a broad incumbent.

Does Lytix Biopharma have an API?

No public API is recorded for Lytix Biopharma.

What industry is Lytix Biopharma in?

Lytix Biopharma's product category is Immuno-oncology Therapeutics. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingLytix Biopharma Clarifies Subsequent Offering Is Capped at 1,875,000 New SharesLytix Biopharma corrected its November 18, 2026, announcement to cap the subsequent offering at 1,875,000 new shares. The offering would raise up to NOK 15 million at NOK 8 per share, with the company retaining the right to cancel if shares trade at or below the subscription price.The future of tradingCorrection: Lytix Biopharma ASA: Key information relating to the subsequent offeringLytix Biopharma ASA announced a correction to its stock exchange announcement, adding the maximum number of new shares for its subsequent offering. The subsequent offering will issue up to 1,875,000 new shares at NOK 8.00 each, raising gross proceeds of up to NOK 15 million. Whether the offering is carried out is subject to completion of the private placement and retail offering, board resolution, prospectus, and market conditions.news.cision.comCorrection: Lytix Biopharma ASA: Key information relating to the subsequent offeringLytix Biopharma corrected its announcement on the Subsequent Offering, adding that up to 1,875,000 new shares at NOK 8.00 each will be issued, raising gross proceeds of up to NOK 15 million. The offering is subject to completion of the Private Placement and Retail Offering, board approval, and market conditions.Dealroom.coLytix Biopharma raises $8.36M post-IPO to prep melanoma Phase III | Dealroom NewsLytix Biopharma raised $8.36M post-IPO via private placement and retail offering, with largest shareholders pre-committing. Proceeds fund Phase III readiness for its ruxotemitide melanoma therapy, following a positive Phase II study. The company said the pivotal trial requires additional financing or a partner.news.cision.comLytix Biopharma ASA: Ex. subsequent offeringLytix Biopharma completed a private placement and retail offering raising NOK 80 million, with a subsequent offering to existing shareholders at NOK 8.00 per share. The shares are traded exclusive of the right to participate in the subsequent offering from today.news.cision.comLytix Biopharma ASA: Key information relating to the subsequent offeringLytix Biopharma announced a Subsequent Offering of new shares at NOK 8.00 per share, directed to eligible existing shareholders. The offering, if carried out, would raise up to NOK 15 million in gross proceeds, subject to completion of prior offerings and market conditions.news.cision.comLytix Biopharma ASA – Mandatory notification of trade by close associates to primary insidersLytix Biopharma announced a private placement and retail offering of 10 million new shares at NOK 8.00 each. Close associates of primary insiders were allocated shares, and Saturn Invest AS lent 1,118,247 existing shares to DNB Carnegie to facilitate delivery-versus-payment settlement.news.cision.comLytix Biopharma ASA: Private placement and retail offer via Nordnet successfully completedLytix Biopharma completed a private placement and retail offering via Nordnet, raising NOK 80 million in gross proceeds. The capital will fund Phase III readiness for ruxotemitide in neoadjuvant melanoma and advance LTX-401. A subsequent offering of up to NOK 15 million is planned for existing shareholders.news.cision.comLytix Biopharma ASA: Contemplated private placement and retail offer via NordnetLytix Biopharma announced a private placement and retail offering via Nordnet, with DNB Carnegie as bookrunner. The offering raises NOK 60-80 million gross, at NOK 8.00 per share, with applications open 17-18 November 2026. Proceeds will fund Phase III readiness and working capital, with Phase III expected in 2027.Investing.comEarnings call transcript: Lytix Biopharma falls 8.4% after q3 2026 updateLytix Biopharma reported that its NeoLIPA study of ruxotemitide in melanoma met its primary endpoint of pathologic complete response, and the FDA indicated a single Phase III study may suffice for U.S. approval. The stock fell 8.37% to $8.98 after the Q3 2026 update, with cash burn improving to NOK 24.1 million and cash of NOK 67.3 million.